Protalix BioTherapeutics, Inc. Annual Current Income Tax Expense (Benefit) in USD from 2022 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.
Summary
Protalix BioTherapeutics, Inc. quarterly/annual Current Income Tax Expense (Benefit) history and growth rate from 2022 to 2023.
  • Protalix BioTherapeutics, Inc. Current Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $164K, a 72.6% increase year-over-year.
  • Protalix BioTherapeutics, Inc. annual Current Income Tax Expense (Benefit) for 2023 was $3.35M, a 531% increase from 2022.
Current Income Tax Expense (Benefit), Trailing 12 Months (USD)
Current Income Tax Expense (Benefit), Annual (USD)
Current Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $3.35M +$2.82M +531% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-14
2022 $530K Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.